1-(2-苯基环己基)乙酮 | 23923-61-7

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 1-(2-苯基环己基)乙酮
• 英文名称: 3-(2-phenylcyclohexyl)-1-ethanone
• 英文别名: 1-(2-phenyl-cyclohexyl)-ethanone；2¹-Oxo-2-aethyl-diphenyl-hexahydrid-(1.2.3.4.5.6)；1-(2-Phenyl-cyclohexyl)-aethanon；2'-Phenyl-hexahydroacetophenon；1-(2-Phenylcyclohexyl)ethanone
• CAS: 23923-61-7
• 化学式: C₁₄H₁₈O
• 分子量: 202.296
• InChiKey: HZIAUPWBCOWHDF-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.4
• 重原子数：
  15
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  17.1
• 氢给体数：
  0
• 氢受体数：
  1

反应信息

• 作为产物：
  描述：

  alkaline earth salt of/the/ methylsulfuric acid 在 氢氧化钾 作用下， 生成 2-phenylcyclohexane-1-carboxylic acid 、 1-(2-苯基环己基)乙酮
  参考文献：
  名称：

  Kipping; Perkin, Journal of the Chemical Society, 1890, vol. 57, p. 311

  摘要：

  DOI：

文献信息

• Hepatitis C Virus Inhibitors
  申请人：Bristol-Myers Squibb Company

  公开号：US20130183269A1

  公开（公告）日：2013-07-18

  The present disclosure is generally directed to antiviral compounds, and more specifically directed to combinations of compounds which can inhibit the function of the NS5A protein encoded by Hepatitis C virus (HCV), compositions comprising such combinations, and methods for inhibiting the function of the NS5A protein.

  本公开涉及抗病毒化合物，更具体地涉及能够抑制丙型肝炎病毒（HCV）编码的NS5A蛋白功能的化合物组合，包括这种组合的组成物，以及抑制NS5A蛋白功能的方法。
• NITROGEN-CONTAINING SATURATED HETEROCYCLIC COMPOUND
  申请人：SUMITOMO CHEMICAL COMPANY, LIMITED

  公开号：US20160221948A1

  公开（公告）日：2016-08-04

  The present invention provides a compound represented by the following formula (I) or its pharmaceutically acceptable salt: [wherein, R 1 represents optionally substituted C 1-4 alkyl, n shows integer of 1 to 4, R 2 represents optionally substituted C 1-4 alkyl or hydrogen atom, R 3 represents optionally substituted C 1-4 alkyl, R 4a , R 4b , R 4c , and R 4d , similarly or differently, represent optionally substituted C 6-14 aryl, optionally substituted C 1-4 alkyl, or hydrogen atom and the like, A represents optionally substituted C 6-14 aryl or optionally substituted 5 to 11 membered heteroaryl].

  本发明提供了一种由下式(I)表示的化合物或其药用可接受的盐： [其中，R1表示可选地取代的C1-4烷基，n表示1到4的整数，R2表示可选地取代的C1-4烷基或氢原子，R3表示可选地取代的C1-4烷基，R4a、R4b、R4c和R4d，相同或不同，表示可选地取代的C6-14芳基，可选地取代的C1-4烷基，或氢原子等，A表示可选地取代的C6-14芳基或可选地取代的5至11成员的杂芳基]。
• Palladium(II)-Catalyzed Michael-Type Addition Reactions Using Aryltin Compounds
  作者：Toshiyuki Ohe、Takeshi Wakita、Shin-ichi Motofusa、Chan Sik Cho、Kouichi Ohe、Sakae Uemura

  DOI：10.1246/bcsj.73.2149

  日期：2000.9

  A variety of aryltin compounds can be employed for Michael-type hydroarylation reactions to α,β-unsaturated ketones and aldehydes in the presence of a catalytic amount of palladium(II) salt in acetic acid under air. Each reaction is much accelerated in the presence of a soluble metal chloride such as LiCl, MgCl2, and CaCl2. It is found that slightly fewer than four aryl groups of tetraaryltins can

  多种芳基锡化合物可用于在乙酸中在催化量的钯 (II) 盐存在下，在空气中进行迈克尔型加氢芳基化反应，生成 α,β-不饱和酮和醛。在可溶性金属氯化物如 LiCl、MgCl2 和 CaCl2 的存在下，每个反应都会大大加速。发现在该芳基化反应中，四芳基锡的芳基略少于四个可以转移到产物中。
• HEPATITIS C VIRUS INHIBITORS
  申请人：BRISTOL-MAYERS SQUIBB COMPANY

  公开号：US20160199355A1

  公开（公告）日：2016-07-14

  The present disclosure is generally directed to antiviral compounds, and more specifically directed to combinations of compounds which can inhibit the function of the NS5A protein encoded by Hepatitis C virus (HCV), compositions comprising such combinations, and methods for inhibiting the function of the NS5A protein.

  本公开涉及抗病毒化合物，更具体地涉及能够抑制丙型肝炎病毒（HCV）编码的NS5A蛋白功能的化合物组合、包含这种组合的组合物，以及抑制NS5A蛋白功能的方法。
• Combinations of Hepatitis C Virus Inhibitors
  申请人：BRISTOL-MYERS SQUIBB COMPANY

  公开号：US20160158200A1

  公开（公告）日：2016-06-09

  The present disclosure is generally directed to antiviral compounds, and more specifically directed to combinations of compounds which can inhibit the function of the NS5A protein encoded by Hepatitis C virus (HCV), compositions comprising such combinations, and methods for inhibiting the function of the NS5A protein.

  本公开涉及抗病毒化合物，更具体地涉及能够抑制丙型肝炎病毒（HCV）编码的NS5A蛋白功能的化合物组合，包含这种组合的组合物，以及抑制NS5A蛋白功能的方法。